Agenus | AGEN - Des Atouts





Des Atouts Changement Date
AbbVie USD 133.96B 62M 2025-12
Agenus USD 226.8M 7.09M 2025-12
Amgen USD 90.59B 445M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Celldex Therapeutics USD 582.98M 65.46M 2025-12
CSL USD 37.9B 1.5B 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Incyte USD 6.96B 627.62M 2025-12
Intrexon USD 73.16M 77.88M 2024-06
J&J USD 199.21B 6.39B 2025-12
Jiangsu Hengrui CNY 68.33B 5.43B 2025-09
Karyopharm Therapeutics USD 96.23M 8.65M 2025-09
MacroGenics USD 256.85M 13.92M 2025-12
Merck EUR 51.53B 600M 2025-12
Merck USD 129.55B 12.02B 2025-09
Northwest Biotherapeutics USD 30.61M 1.06M 2025-09
Novartis USD 110.95B 3.66B 2025-12
Novavax USD 1.18B 3.38M 2025-12
Pfizer USD 208.73B 2.64B 2025-09
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Veracyte USD 1.41B 38.23M 2025-12